MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
On September 22, 2017, MabVax Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with select accredited investors relating to the Company’s registered direct offering, issuance and sale (the “Offering”) of 2,016,129 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share. The purchase price per Share was $0.62.
Proceeds from the Offering shall be used to continue clinical studies currently underway for the Company’s therapeutic antibodies and for working capital and general corporate purposes.
A copy of the form of Securities Purchase Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K.
The net proceeds to the Company from the Offering, after deducting the Company’s estimated offering expenses, are expected to be approximately $1.2 million. The Offering is expected to close on or before September 27, 2017.
The foregoing summaries of the terms of the Subscription Agreement are subject to, and qualified in their entirety by, such documents attached hereto as Exhibit 10.1, and incorporated herein by reference.
Item 8.01 Other Events.
On September 22, 2017, the Company issued a press release announcing the registered direct offering. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit |
|
|
No. |
Description |
|
Opinion of Sichenzia Ross Ference Kesner LLP |
|
|
Form of Subscription Agreement, dated September 22, 2017 |
|
|
Press Release dated September 22, 2017 |
MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-5.1 2 ex5-1.htm OPINION Ex 5-1 Exhibit 5.1 September 22,…To view the full exhibit click here